Zynex (ZYXI) Q1 2025: TRICARE Suspension Drives 43% Revenue Drop, Restructuring Targets $35M Cost Savings

April 29, 2025 | By EarningsIQ Research

TRICARE’s payment suspension triggered a sharp revenue reset for Zynex, exposing payer concentration risk and forcing a rapid operational overhaul. Management is aggressively cutting costs and repositioning the sales force to offset lost TRICARE volume, while banking on the upcoming NECO laser pulse oximeter launch to diversify growth. The next 40 days will determine whether Zynex’s core reimbursement model regains stability or faces a prolonged reset.

Summary

• TRICARE Payment Freeze Exposes Revenue Fragility: Suspension of a key payer’s payments forced Zynex to exclude related revenue, highlighting single-payer dependency.
• Cost Structure Reset Underway: Management is executing a $35M annual expense reduction, including a 15% staff cut, to restore profitability.
• NECO Launch Looms as 2026 Growth Catalyst: FDA submission for the bias-free laser pulse oximeter is imminent, with commercialization targeted for next year.

Performance Analysis

Zynex’s Q1 2025 results reflect the acute impact of the TRICARE payment suspension, with revenue dropping to $26.6 million from $46.5 million a year ago. Device and supplies revenue fell sharply, and gross margin compressed to 69% from 80%, underscoring the outsized influence of payer mix on profitability. Management explicitly excluded all TRICARE-related revenue from Q1, pending resolution of the payment freeze.

Cost containment is moving rapidly, with a 28% reduction in sales and marketing expenses tied to a 15% headcount cut. General and administrative (G&A) costs increased slightly, reflecting restructuring and legal expenses. The company posted a net loss of $10.4 million and negative adjusted EBITDA of $11.8 million, a reversal from modest profitability last year. Despite these headwinds, Zynex maintains $24 million in cash and $40 million in working capital, providing a buffer as it navigates the reimbursement disruption.

• Revenue Model Sensitivity: The abrupt removal of TRICARE revenue demonstrates high exposure to payer decisions in Zynex’s insurance reimbursement-driven business model.
• Margin Compression: Lower revenue base and product mix shift reduced gross margin by 11 percentage points year-over-year.
• Cash Preservation: Liquidity remains solid, but ongoing losses will pressure reserves if reimbursement is not restored promptly.

Order flow from non-TRICARE payers remains stable, with a rising share of non-NEXWAY products (now 34% of orders), signaling some early success in diversification efforts. However, the near-term financial trajectory hinges on both the TRICARE outcome and cost discipline execution.

Executive Commentary

Strategic Positioning

1. Payer Concentration and Revenue Diversification

TRICARE’s payment suspension exposed a critical vulnerability: Zynex’s business model relies on obtaining prescriptions and billing over 3,000 insurance payers, but TRICARE’s abrupt halt had an outsized impact. Management is now actively repositioning the sales force to focus on non-TRICARE opportunities, including personal injury and other private insurers, to rebuild a more balanced revenue mix.

2. Cost Structure Overhaul

A $35 million annual expense reduction is underway, driven by a 15% staff reduction and targeted cuts in sales and corporate overhead. This restructuring is designed to right-size the business for a scenario without TRICARE revenue and to restore profitability even at a lower revenue base. The company is also trimming underperforming sales territories and reallocating resources to higher-potential channels.

3. NECO Pulse Oximeter as Growth Engine

The NECO laser pulse oximeter is positioned as a 2026 inflection point. With FDA submission imminent and commercialization prep underway, Zynex is targeting a large, underserved market. The device aims to address skin pigmentation bias and provide more accurate readings than current LED-based competitors, with the potential to drive significant new revenue once approved.

4. Product Mix and Sales Force Productivity

Non-NEXWAY products now comprise 34% of orders, up from 30% last year, indicating early traction in product diversification. Management is emphasizing higher productivity among sales reps and is willing to leave territories open rather than maintain underperformers, signaling a shift toward quality over quantity in sales execution.

Key Considerations

This quarter marks a strategic reset for Zynex, as management attempts to turn a reimbursement crisis into a catalyst for operational discipline and product innovation. The outcome of the TRICARE review will determine the near-term recovery path, but the company is acting decisively to control what it can.

Key Considerations:

• Payer Risk Management: The TRICARE episode underscores the need for further payer diversification and less reliance on any single reimbursement stream.
• Expense Discipline: Execution of $35 million in cost savings is essential to stem cash burn and restore margin leverage.
• NECO Commercialization Timeline: FDA approval and successful launch of the NECO oximeter could materially shift the growth narrative in 2026 and beyond.
• Sales Force Redeployment: Refocusing on higher-potential payers and products will test the company’s ability to offset lost TRICARE volumes in the next several quarters.

Risks

Prolonged TRICARE payment suspension or a negative outcome could extend revenue pressure, forcing deeper cost cuts and raising the risk of further cash burn. There is also uncertainty around the timing and magnitude of NECO commercialization, and whether payer concentration risk can be mitigated quickly enough. Regulatory, payer, and competitive dynamics remain material uncertainties.

Forward Outlook

For Q2 2025, Zynex guided to:

• Revenue of $27 million
• EPS loss of $0.20 per share

For full-year 2025, management withheld guidance pending TRICARE resolution but indicated plans to provide an update with Q2 results.

• Q2 guidance excludes any TRICARE revenue, mirroring Q1 methodology.
• Management expects to complete cost restructuring and reposition for growth regardless of TRICARE outcome.

Takeaways

The TRICARE suspension forced a rapid strategic pivot and exposed the business model’s payer risk. Zynex’s ability to execute on cost cuts and drive non-TRICARE growth will determine its recovery trajectory. The NECO laser oximeter offers a credible path to future diversification, but near-term stability depends on operational discipline and the outcome of the TRICARE review.

• Revenue Fragility Highlighted: Single-payer exposure can quickly disrupt financial performance and market confidence, as seen this quarter.
• Restructuring as a Prerequisite: Cost discipline and sales force realignment are not optional but necessary for survival and recovery.
• Investors Should Watch: TRICARE decision (due within 40 days), pace of expense reduction, and progress on NECO FDA submission and launch readiness.

Conclusion

Zynex’s Q1 2025 results mark a turning point, with management forced to confront payer risk and operational inefficiency head-on. The next phase hinges on the TRICARE outcome and the company’s ability to execute a leaner, more diversified growth strategy anchored by its upcoming NECO product.

Industry Read-Through

The Zynex quarter is a cautionary tale for medtech and device companies reliant on insurance reimbursement, demonstrating how quickly payer actions can upend revenue and force structural change. The episode highlights the importance of payer diversification, operational agility, and pipeline innovation. NECO’s focus on eliminating skin pigmentation bias in pulse oximetry is likely to resonate across the patient monitoring sector, potentially setting a new standard for clinical accuracy and health equity. Competitors and adjacent companies should assess their own payer risk exposure and readiness to adapt to sudden reimbursement shifts.

ZYXI Healthcare Medical Devices Reimbursement Pulse Oximetry Cost Restructuring Payer Risk